Radiopharm Theranostics (ASX:RAD) secured regulatory approval to expand its phase 1 trial investigating the safety and tolerability of 177Lu-RAD204, a treatment candidate for non-small cell lung cancer, according to a Tuesday filing with the Australian bourse.
Specifically, the Australian Human Research Ethics Committee cleared the trial to include five other forms of cancer with programmed death-ligand 1 (PD-L1) expressing solid tumors, such as PD-L1 positive small cell lung cancer, triple-negative breast cancer, melanoma, head and neck cancer, and endometrial cancer, the filing said.
The trial is currently underway at four sites across Australia, as per the filing.
Radiopharm Theranostics' shares were up almost 4% in recent Tuesday trade.
Price (AUD): $0.03, Change: $+0.001, Percent Change: +3.84%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。